Troubled waters at Clínica Las Condes: Carlos Gil presents his “indeclinable” resignation to the board of directors and vice-presidency of the institution



[ad_1]

In Clinicas Las Condes the waters do not calm down. Of course, because in the midst of the conflict with the doctors, the institution announced this afternoon the “unwavering” resignation of Carlos Gil del Canto from his position as director and vice president.

CLC reported this through a brief essential fact sent to the CMF, in which, however, it does not provide details of the reasons for its departure.

Carlos Gil del Canto was not only the vice president of the board; He is also the cousin of the chairman of the board, Alejandro Gil, who in turn is the husband of the final controller of the institution, Cecilia Karlezi.

And it is not the first time that he resigned from CLC since he also did so at the beginning of 2018, when he was not yet one year old as director of the institution.

However, later through other essential facts, the institution specified that the departure of the manager is due to health reasons. Along these lines, the institution released Carlos Gil’s resignation letter in which he thanked Alejandro Gil and Cecilia Karlezi for their support.

The announcement of the clinic, which reported losses of more than $ 10,000 million in the first semester, coincides with the tense situation that exists inside the emblematic health institution in the eastern sector of the capital.

This week the medical staff of Clínica Las Condes (CLC), made up of more than 500 professionals, decided to make public its vision and concern regarding the decisions that the administration and the board of directors of said institution have taken, since the Auguri Group, family investment office linked to Cecilia Karlezi.

A relevant point that triggers this action by the medical body is the new lease that the clinic intends to impose.

“The CLC board of directors seeks to terminate, unilaterally, the lease contract with each of the doctors who attend the institution, without complying with the deadlines and formalities required by law, in addition to revealing an economic approach to the health ”, said José Giordano, president of the executive committee of the medical body of CLC.

The health professional added that “given this scenario it is that, together with our team of external advisers, we are evaluating the different courses of legal and administrative action, to enforce our rights and protect our clinic and its patients.”

According to information published by Pulso yesterday, the representatives of the medical body indicate that they understand the reality of CLC and have expressed their willingness to enter into a review process of the current link. However, they assure that this new contract proposal that is being imposed does not take care of the reality of CLC and of an “essential common project”.

“We believe that the actions being taken by the clinic’s board of directors and its new controlling shareholder, the Auguri Group, collide head-on with the spirit of service and dialogue that should prevail in our society, today more than ever,” said José Giordano.

The representative of the CLC doctors points out that the new contract deteriorates the working conditions of the clinic’s health professionals, establishing incentives that are at odds with good practices. To which is added the fact that the medical gaze would be being left aside from the analysis. “Here we must work to build a relationship that benefits all parties, especially our patients, that responds to the needs of current medicine, and that projects CLC with the commitment of all, allowing it to continue to be a bastion of the cooperation of public-private health ”, concluded the president of the executive committee of the CLC medical body.

Clínica Las Condes is linked to Cecilia Karlezi, businesswoman who is a partner of Falabella, Cruzados, Enaex, Moller & Pérez-Cotapos and the Hipódromo de Chile, among other companies, and which took control of the property of CLC last November, when it went from 27.37% of the shares to 50.0052% in exchange for an outlay of almost $ 76 billion.



[ad_2]